Ardelyx (ARDX) News Today $5.01 -0.15 (-2.91%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Ardelyx's (ARDX) "Neutral" Rating Reiterated at HC WainwrightJanuary 18 at 2:07 AM | americanbankingnews.comHennion & Walsh Asset Management Inc. Acquires 164,480 Shares of Ardelyx, Inc. (NASDAQ:ARDX)Hennion & Walsh Asset Management Inc. grew its holdings in shares of Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 25.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 808,392 shares of the biopharmJanuary 17 at 5:34 AM | marketbeat.comArdelyx’s Mixed Financial Outlook: Hold Rating Amid IBSRELA Growth and XPHOZAH ChallengesJanuary 16 at 7:44 PM | markets.businessinsider.comArdelyx (NASDAQ:ARDX) Earns Neutral Rating from HC WainwrightHC Wainwright restated a "neutral" rating and set a $5.50 price target on shares of Ardelyx in a research note on Thursday.January 16 at 11:51 AM | marketbeat.comArdelyx (NASDAQ:ARDX) Shares Up 8.3% - Still a Buy?Ardelyx (NASDAQ:ARDX) Stock Price Up 8.3% - What's Next?January 15 at 5:59 PM | marketbeat.comArdelyx (NASDAQ:ARDX) Stock Price Down 3.7% - Time to Sell?Ardelyx (NASDAQ:ARDX) Trading Down 3.7% - What's Next?January 15 at 3:53 PM | marketbeat.comArdelyx’s Strategic Outlook and Financial Strength Indicate Strong Buy PotentialJanuary 15 at 2:49 PM | markets.businessinsider.comTD Cowen Remains a Buy on Ardelyx (ARDX)January 14, 2025 | markets.businessinsider.comArdelyx, Inc.: Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic PrioritiesJanuary 14, 2025 | finanznachrichten.deArdelyx's Ibsrela sales beat expectations, shares surgeJanuary 14, 2025 | in.investing.comArdelyx reports preliminary Q4 IBSRELA revenue $54MJanuary 14, 2025 | markets.businessinsider.comArdelyx (NASDAQ:ARDX) Stock Price Up 8.3% - What's Next?Ardelyx (NASDAQ:ARDX) Shares Up 8.3% - Here's WhyJanuary 13, 2025 | marketbeat.comArdelyx, Inc. Reports Strong Commercial Growth in 2024 with $319 Million in U.S. Net Product Sales and Reaffirms Revenue Expectations for IBSRELA and XPHOZAHJanuary 13, 2025 | quiverquant.comArdelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic PrioritiesJanuary 13, 2025 | globenewswire.comArdelyx, Inc. (NASDAQ:ARDX) CEO Michael Raab Sells 41,666 SharesArdelyx, Inc. (NASDAQ:ARDX - Get Free Report) CEO Michael Raab sold 41,666 shares of the firm's stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $5.31, for a total transaction of $221,246.46. Following the completion of the transaction, the chief executive officer now owns 1,129,552 shares in the company, valued at $5,997,921.12. This represents a 3.56 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.January 10, 2025 | marketbeat.comArdelyx (NASDAQ:ARDX) Shares Up 5.8% - Should You Buy?Ardelyx (NASDAQ:ARDX) Stock Price Up 5.8% - Time to Buy?January 7, 2025 | marketbeat.comArdelyx to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 6, 2025 | globenewswire.comArdelyx, Inc. (NASDAQ:ARDX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Ardelyx, Inc. (NASDAQ:ARDX - Get Free Report) have been given an average rating of "Moderate Buy" by the nine ratings firms that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendationJanuary 6, 2025 | marketbeat.comPrincipal Financial Group Inc. Lowers Position in Ardelyx, Inc. (NASDAQ:ARDX)Principal Financial Group Inc. trimmed its holdings in Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 71.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 135,439 shares of the biopharmaceuticJanuary 5, 2025 | marketbeat.comArdelyx price target lowered to $8 from $11 at JefferiesJanuary 2, 2025 | markets.businessinsider.comBeyond The Numbers: 4 Analysts Discuss Ardelyx StockJanuary 2, 2025 | benzinga.comJefferies Financial Group Issues Pessimistic Forecast for Ardelyx (NASDAQ:ARDX) Stock PriceJefferies Financial Group lowered their price objective on Ardelyx from $11.00 to $8.00 and set a "buy" rating for the company in a research report on Thursday.January 2, 2025 | marketbeat.comArdelyx (NASDAQ:ARDX) Stock Price Down 3.8% - Here's WhyArdelyx (NASDAQ:ARDX) Shares Down 3.8% - Should You Sell?December 31, 2024 | marketbeat.comWhy Ardelyx (ARDX) Is One of the Best Biotech Penny Stocks to Invest in Now?December 30, 2024 | msn.comArdelyx (NASDAQ:ARDX) Stock Price Up 4.6% - What's Next?Ardelyx (NASDAQ:ARDX) Shares Up 4.6% - Should You Buy?December 27, 2024 | marketbeat.comArdelyx (NASDAQ:ARDX) Shares Gap Up After Insider Buying ActivityArdelyx (NASDAQ:ARDX) Shares Gap Up on Insider Buying ActivityDecember 24, 2024 | marketbeat.comDavid M. Mott Buys 213,300 Shares of Ardelyx, Inc. (NASDAQ:ARDX) StockDecember 24, 2024 | insidertrades.comArdelyx, Inc. (NASDAQ:ARDX) Director David M. Mott Purchases 213,300 SharesArdelyx, Inc. (NASDAQ:ARDX - Get Free Report) Director David M. Mott purchased 213,300 shares of the business's stock in a transaction on Thursday, December 19th. The stock was purchased at an average price of $4.67 per share, for a total transaction of $996,111.00. Following the acquisition, the director now owns 1,638,765 shares of the company's stock, valued at approximately $7,653,032.55. This represents a 14.96 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.December 23, 2024 | marketbeat.comBarclays PLC Has $3.77 Million Position in Ardelyx, Inc. (NASDAQ:ARDX)Barclays PLC raised its stake in Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 24.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 547,325 shares of the biopharmaceutical company's stock after buying an additional 109,285 shares during thDecember 23, 2024 | marketbeat.comArdelyx: A Small Bet Its Latest Setback Will Be TemporaryDecember 20, 2024 | seekingalpha.comArdelyx (NASDAQ:ARDX) Sets New 1-Year Low - Should You Sell?Ardelyx (NASDAQ:ARDX) Sets New 52-Week Low - Time to Sell?December 18, 2024 | marketbeat.comArdelyx (NASDAQ:ARDX) Shares Down 6.5% - Here's What HappenedArdelyx (NASDAQ:ARDX) Trading Down 6.5% - Should You Sell?December 17, 2024 | marketbeat.comArdelyx, Inc. (NASDAQ:ARDX) Stake Boosted by State Street CorpState Street Corp grew its stake in shares of Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 1.5% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,141,850 shares of the biopharmaceutical compDecember 17, 2024 | marketbeat.comInsider Selling: Ardelyx, Inc. (NASDAQ:ARDX) CEO Sells 25,000 Shares of StockDecember 13, 2024 | insidertrades.comArdelyx, Inc. (NASDAQ:ARDX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesArdelyx, Inc. (NASDAQ:ARDX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight research firms that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issuDecember 12, 2024 | marketbeat.comBNP Paribas Financial Markets Grows Position in Ardelyx, Inc. (NASDAQ:ARDX)BNP Paribas Financial Markets lifted its position in shares of Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 274.3% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 181,387 shares of the biopharmaceutical company's stock after purchasing an additional 132,92December 10, 2024 | marketbeat.comPotential Growth for Ardelyx’s Ibsrela Amidst Market VolatilityDecember 7, 2024 | markets.businessinsider.comArdelyx FY2027 EPS Estimate Increased by Leerink PartnrsArdelyx, Inc. (NASDAQ:ARDX - Free Report) - Investment analysts at Leerink Partnrs upped their FY2027 earnings per share estimates for shares of Ardelyx in a research report issued on Wednesday, December 4th. Leerink Partnrs analyst R. Ruiz now expects that the biopharmaceutical company will postDecember 6, 2024 | marketbeat.comRedmile Group LLC Cuts Stock Holdings in Ardelyx, Inc. (NASDAQ:ARDX)Redmile Group LLC reduced its position in shares of Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 11.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,660,763 shares of the biopharmaceutical company's stoDecember 5, 2024 | marketbeat.comArdelyx, Inc. (NASDAQ:ARDX) Shares Sold by Janus Henderson Group PLCJanus Henderson Group PLC trimmed its holdings in Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 17.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 21,529,880 shares of the biopharmaceutical company's stock after selling 4,4December 5, 2024 | marketbeat.comEventide Asset Management LLC Has $51.08 Million Stock Holdings in Ardelyx, Inc. (NASDAQ:ARDX)Eventide Asset Management LLC raised its holdings in shares of Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 11.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 7,413,049 shares of the biopharmaceutical company's stock after acquiring an additional 746,067November 29, 2024 | marketbeat.comVestal Point Capital LP Acquires Shares of 500,000 Ardelyx, Inc. (NASDAQ:ARDX)Vestal Point Capital LP purchased a new stake in shares of Ardelyx, Inc. (NASDAQ:ARDX - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 500,000 shares of the biopharmaceutical company's stoNovember 29, 2024 | marketbeat.comMichael Raab Sells 25,000 Shares of Ardelyx, Inc. (NASDAQ:ARDX) StockNovember 28, 2024 | insidertrades.comRubric Capital Management LP Buys 1,243,606 Shares of Ardelyx, Inc. (NASDAQ:ARDX)Rubric Capital Management LP grew its stake in shares of Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 68.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,060,191 shares of the biopharmaceutical company's stock afterNovember 27, 2024 | marketbeat.comPropel Bio Management LLC Has $7.38 Million Position in Ardelyx, Inc. (NASDAQ:ARDX)Propel Bio Management LLC raised its position in Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 15.8% during the third quarter, according to its most recent filing with the SEC. The firm owned 1,070,947 shares of the biopharmaceutical company's stock after purchasing an additional 146,364 shares duriNovember 26, 2024 | marketbeat.comArdelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save ItNovember 24, 2024 | seekingalpha.comPrincipal Financial Group Inc. Has $933,000 Stock Position in Ardelyx, Inc. (NASDAQ:ARDX)Principal Financial Group Inc. lessened its holdings in shares of Ardelyx, Inc. (NASDAQ:ARDX - Free Report) by 71.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 135,439 shares of the biopharmaceuNovember 24, 2024 | marketbeat.comInsider Selling: Ardelyx, Inc. (NASDAQ:ARDX) CFO Sells 5,260 Shares of StockNovember 23, 2024 | insidertrades.comArdelyx, Inc. (NASDAQ:ARDX) CFO Sells $25,195.40 in StockArdelyx, Inc. (NASDAQ:ARDX - Get Free Report) CFO Justin A. Renz sold 5,260 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $4.79, for a total value of $25,195.40. Following the completion of the transaction, the chief financial officer now owns 291,139 shares of the company's stock, valued at approximately $1,394,555.81. This trade represents a 1.77 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.November 22, 2024 | marketbeat.comArdelyx, Inc. (NASDAQ:ARDX) Insider Laura A. Williams Sells 7,366 SharesArdelyx, Inc. (NASDAQ:ARDX - Get Free Report) insider Laura A. Williams sold 7,366 shares of the firm's stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $4.79, for a total transaction of $35,283.14. Following the completion of the sale, the insider now directly owns 308,745 shares in the company, valued at approximately $1,478,888.55. This trade represents a 2.33 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.November 22, 2024 | marketbeat.com Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Email Address ARDX Media Mentions By Week ARDX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARDX News Sentiment▼0.580.68▲Average Medical News Sentiment ARDX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARDX Articles This Week▼149▲ARDX Articles Average Week Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CYTK News Today NUVL News Today GRFS News Today VKTX News Today AXSM News Today TGTX News Today KRYS News Today OGN News Today SRRK News Today ADMA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARDX) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARDX Stock Alerts